Loading your page…
Loading your page…

Published by American Association of Hip and Knee Surgeons (AAHKS), American Society of Regional Anesthesia and Pain Medicine (ASRA), American Academy of Orthopaedic Surgeons (AAOS), Hip Society, and Knee Society · AAOS Clinical Practice Guidelines and Systematic Review Methodology
This clinical practice guideline provides evidence-based recommendations regarding the use of opioids before, during, and after primary total joint arthroplasty (TJA). It highlights the risks of preoperative opioid use, advocates for prescribing the lowest effective quantity at discharge, and details the effects of perioperative opioids.
Key Takeaways
Preoperative opioid use is associated with inferior patient reported outcomes, increased opioid consumption after surgery, an increased risk for chronic opioid use, and an increased risk of complications after TJA.
Reduction of opioid use prior to TJA may lead to improved patient reported outcomes after TJA compared to patients who do not reduce opioid consumption prior to surgery.
An opioid administered immediately prior to surgery reduces postoperative pain and opioid consumption within the first 72 hours after TJA, but may increase the risk of complications, such as respiratory depression or sedation, especially if combined with other opioids administered intraoperatively or postoperatively.
An opioid administered intraoperatively reduces opioid consumption, but does not affect postoperative pain within 72 hours after surgery. An opioid administered intraoperatively may increase the risk of complications, such as respiratory depression or sedation, especially if combined with other opioids administered preoperatively or postoperatively.
Scheduled opioid administration without multimodal analgesia within 72 hours after primary TJA reduces the need for additional opioid pain medications for breakthrough pain and may reduce postoperative pain within 72 hours after surgery, but providing scheduled opioids is discouraged. Scheduled opioid administration postoperatively may increase the risk of complications, such as respiratory depression and sedation, especially if combined with other opioids administered during the perioperative period.
Prescribing lower quantities of opioid pills at discharge may lead to equivalent patient reported outcomes, pain relief, reduced opioid consumption, and fewer unused opioid pills after TJA.
Tramadol administered within 24 hours after surgery may reduce postoperative pain and opioid consumption after TJA within 72 hours after surgery, but may be associated with adverse events such as dizziness and dry mouth.
Clinical Topic
Opioids in Total Joint Arthroplasty
Objectives
To improve the treatment of orthopaedic surgical patients and reduce practice variation by promoting a multidisciplinary evidenced-base approach on the use of opioids following primary TJA.
Target Patient Population
Patients undergoing primary total joint arthroplasty (TJA)
Target Providers
Therapeutic Area
Pain ManagementGuideline Scope
Care Settings
Special Populations
System: AAOS Clinical Practice Guidelines and Systematic Review Methodology
Contraindications
Monitoring Guidance
The cumulative dose of opioids administered as well as the timing between opioid doses must be carefully monitored in TJA patients.
Difficulty
advanced
Learning Paths